InSilicoTrials Technologies
Hyper-accelerate drug and medical device development. Computational models and AI allow to dramatically accelerate the development of new drugs and medical devices, reduce, refine and replace tests on animals and clinical trials, improve the safety of medical products, and significantly cut R&D costs.
InSilicoTrials has built an online platform, where Modeling & Simulation is easy to use, regulatory compliant, and cost-effective.
Today, Modeling and Simulation can help companies reduce the very long and expensive development, as well as the subsequent registration/certification processes for new drugs and medical devices up to 50% and greatly accelerate the go-to-market of new products, allowing companies to exploit patents for a longer period. InSilicoTrials solves these problems by selecting and collecting the best models from top researchers around the world and then by integrating them with the solvers in a scalable IT platform, which makes it easier to use validated models without specific computational knowledge, paying only for the used resources.
We cover the entire process with the in silico approach, from preclinical to clinical. Our product portfolio covers a wide range of therapeutical areas and allows our customer to customise the way they want to work with us.
In silico trials allow to get in a few minutes or hours, instead of weeks, outcomes that are more reliable and already compliant with regulatory guidelines.
Today, Modeling and Simulation can help companies reduce the very long and expensive development, as well as the subsequent registration/certification processes for new drugs and medical devices up to 50% and greatly accelerate the go-to-market of new products, allowing companies to exploit patents for a longer period. InSilicoTrials solves these problems by selecting and collecting the best models from top researchers around the world and then by integrating them with the solvers in a scalable IT platform, which makes it easier to use validated models without specific computational knowledge, paying only for the used resources.
We cover the entire process with the in silico approach, from preclinical to clinical. Our product portfolio covers a wide range of therapeutical areas and allows our customer to customise the way they want to work with us.
In silico trials allow to get in a few minutes or hours, instead of weeks, outcomes that are more reliable and already compliant with regulatory guidelines.
Mario Torchia
VP sales and marketing
Luca Emili
CEO (founder & CEO)
